ArticleFrontiers in medicine2026
Case Report: Three rare cases of pseudomyogenic hemangioendothelioma with atypical skeletal involvement.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pseudomyogenic hemangioendothelioma (PHE) is a rare vascular neoplasm of intermediate malignant potential that predominantly affects young adult men and most frequently arises in the lower extremities. Involvement of unusual skeletal sites is uncommon, and the nonspecific imaging features of PHE may contribute to diagnostic uncertainty. Case report: We report three cases of PHE involving unusual osseous locations, including the thoracic spine, femur, and humerus, with one case showing concomitant soft tissue involvement of the upper arm. Multimodal imaging, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT), demonstrated osteolytic bone destruction, soft tissue extension, heterogeneous enhancement, and increased metabolic activity. All patients underwent individualized surgical management according to tumor location and disease extent. The final diagnosis was established by histopathological and immunohistochemical (IHC) evaluation, particularly FOSB positivity and endothelial marker expression. Conclusion: PHE should be considered in the differential diagnosis of atypical bone and soft tissue lesions, even when they occur at uncommon anatomic sites or in patients outside the typical demographic profile. Comprehensive imaging assessment, histopathological confirmation, individualized treatment, and long-term follow-up are essential for accurate diagnosis and optimal clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.